Slowing neurodegeneration is the most pressing clinical need for multiple sclerosis (MS). In this Review, Woo, Engler and Friese provide a neuron-centric view on inflammation-induced neurodegeneration in MS and discuss key pathways and molecules that can be therapeutically targeted.
- Marcel S. Woo
- Jan Broder Engler
- Manuel A. Friese